{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"DUMAS","nct_id":"NCT05684276","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dumas-nct05684276. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"DUMAS","arms":[{"description":"Neodjuvant treatment:\n\nNivolumab: 360 mg intravenous Q3W Paclitaxel: 200mg/m2 infusion over 3 hours Carboplatin: AUC6 at the end of the Paclitaxel infusion\n\nNeoadjuvant treatment will start within 1-3 days from enrollment. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.\n\nSurgery: Surgery must be done within the 3rd-4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3)\n\nDepending on surgery results the patient will receive:\n\n* Patients with degree of resection 'R0': Adjuvant treatment for 6 months with Nivolumab 480mg QW4\n* Patients with degree of resection 'R1' or 'R2': standard treatment according to local guidelines","label":"Experimental: Neodjuvant treatment + Adjuvant maintenance treatment","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-06-01","type":"ESTIMATED"},"conditions":["NSCLC","Pancoast Tumor"],"enrollment":{"count":22,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Carboplatin","otherNames":["Paraplatin"],"type":"DRUG"},{"name":"Paclitaxel","otherNames":["Taxol"],"type":"DRUG"},{"name":"Nivolumab","otherNames":["Opdivo"],"type":"DRUG"}],"last_update":"2026-05-05","lead_sponsor":"Fundación GECP","official_title":"Phase II Clinical Trial of Neo-adjuvant Chemo/Immunotherapy Followed by Adjuvant Treatment Depending on the Resection Status for the Treatment of NSCLC Patients Diagnosed With Pancoast Tumor. A Multicenter Exploratory Study","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-03-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Estimate progression-free survival (PFS)","timeFrame":"From the date randomization until the date of last follow up, assessed up to 24 months"}],"references":[],"start_date":{"date":"2023-05-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors","url":"https://clinicaltrials.gov/study/NCT05684276"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dumas-nct05684276"}